Immunosuppressants

Version vom 8. Juli 2020, 09:19 Uhr

Dapsone
32344275 2020. Dapsone, colchicine and olanzapine as treatment adjuncts to prevent COVID-19 associated adult respiratory distress syndrome (ARDS)
32339778 ä. Dapsone and Doxycycline could be potential treatment modalities for COVID-19
31931639 2020. Dapsone as treatment adjunct in ARDS

Cyclophosphamide
32526511 2020. A potential role for cyclophosphamide in the mitigation of acute respiratory distress syndrome among patients with SARS-CoV-2.

Thiopurines azathioprin
32400020 2020. COVID-19 and implications for thiopurine use.

MMF mycophenolic acid
32579258 2020. Antiviral activities of mycophenolic acid and IMD-0354 against SARS-CoV-2.

mTOR ihibitors
32313883 2020. Inhaled biguanides and mTOR inhibition for influenza and coronavirus (Review)
32334502 2020. The Mechanistic Target of Rapamycin (mTOR): Novel Considerations as an Antiviral Treatment
32410266 2020. Immunoregulation with mTOR inhibitors to prevent COVID-19 severity: A novel intervention strategy beyond vaccines and specific antiviral medicines.
32413699 2020. Lithium chloride combination with rapamycin for the treatment of COVID-19 pneumonia.
32578354 2020. Obesity and COVID-19: The mTOR pathway as a possible culprit.

Cyclophilin A inhibitors
32347055 2020. Role of cyclophilin A during coronavirus replication and the antiviral activities of its inhibitors

Alisporivir

Cyclosporin A
32354685 ä. Why choose cyclosporin A as first-line therapy in COVID-19 pneumonia